B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 14559843.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
In this report, we demonstrate that B7-H1, a B7 family molecule implicated in tumor immune evasion, is constitutively expressed on 66% of freshly isolated squamous cell carcinomas of the head and neck (SCCHN). To define the potential impact of tumor-associated B7-H1 on immunotherapy, the B7-H1-negative mouse SCC line, SCCVII, was transfected to express B7-H1. Although all of the animals succumbed to B7-H1/SCCVII tumors even after adoptive T-cell immunotherapy, the infusion of B7-H1 blocking monoclonal antibody with activated T cells cured 60% of animals. These data support B7-H1 blockade as a new approach to enhance the efficacy of T-cell immunotherapy.
Medical subject headings
- B7-1 Antigen
- Blood Proteins
- Carcinoma, Squamous Cell
- Head and Neck Neoplasms
- Immunotherapy, Adoptive
- Peptides